Biochemical Genetics ( IF 2.4 ) Pub Date : 2022-08-16 , DOI: 10.1007/s10528-022-10263-y Mulin Liu 1 , Chang Liu 1 , Xi Li 2 , Shijun Li 1
Evidences indicate that long non-coding RNAs (lncRNAs) are closely involved and contributed to tumorigenesis and cancer progression. As a novel lncRNA, RP11-79H23.3 was found to be an anti-oncogene in bladder cancer. However, the essential roles and functions of RP11-79H23.3 in non-small-cell lung cancer (NSCLC) remains to be elucidated. Here, loss of functional assay was applied to gain insights into the functions of RP11-79H23.3 on the proliferation and metastasis capabilities of A549 and H1299 cells. Meantime, Real-time PCR was utilized to measure RP11-79H23.3 and miR-29c expression in NSCLC tissues. Dual-luciferase reporter assay, CCK8, colony formation assay, transwell and Western blot were performed to illustrate the potential molecular basis of RP11-79H23.3 in NSCLC. RP11-79H23.3 downregulation facilitated cell proliferation, migration, and invasion of NSCLC. The result of dual-luciferase reporter assay represented a direct interaction of RP11-79H23.3 with miR-29c, which suppressed miR-29c expression that showed inversely correlation in NSCLC. Moreover, RP11-79H23.3 siRNA facilitated the progression of NSCLC partially via regulating the expression of miR-29c and the activation of Wnt/β-catenin signaling pathway. Our findings highlighted that RP11-79H23.3, served as an anti-oncogene, accelerated NSCLC progression through sequestering miR-29c, providing a promising therapeutic target for NSCLC.
中文翻译:
RP11-79H23.3通过促进miR-29c抑制非小细胞肺癌的增殖转移
有证据表明,长链非编码 RNA (lncRNA) 与肿瘤发生和癌症进展密切相关并与之相关。作为一种新型 lncRNA,RP11-79H23.3 被发现是膀胱癌的抗癌基因。然而,RP11-79H23.3 在非小细胞肺癌 (NSCLC) 中的重要作用和功能仍有待阐明。在这里,应用功能缺失测定来深入了解 RP11-79H23.3 对 A549 和 H1299 细胞增殖和转移能力的作用。同时,利用实时荧光定量 PCR 检测 NSCLC 组织中 RP11-79H23.3 和 miR-29c 的表达。进行双荧光素酶报告基因测定、CCK8、集落形成测定、transwell 和 Western blot 以说明 RP11-79H23.3 在 NSCLC 中的潜在分子基础。RP11-79H23.3 下调促进细胞增殖、迁移、和NSCLC的侵袭。双荧光素酶报告基因检测结果表明 RP11-79H23.3 与 miR-29c 直接相互作用,抑制 miR-29c 表达,在 NSCLC 中呈负相关。此外,RP11-79H23.3 siRNA部分通过调节miR-29c的表达和Wnt/β-catenin信号通路的激活来促进NSCLC的进展。我们的研究结果强调,RP11-79H23.3 作为一种抗癌基因,通过隔离 miR-29c 加速 NSCLC 进展,为 NSCLC 提供了一个有希望的治疗靶点。3 siRNA部分通过调节miR-29c的表达和Wnt/β-catenin信号通路的激活促进NSCLC的进展。我们的研究结果强调,RP11-79H23.3 作为一种抗癌基因,通过隔离 miR-29c 加速 NSCLC 进展,为 NSCLC 提供了一个有希望的治疗靶点。3 siRNA部分通过调节miR-29c的表达和Wnt/β-catenin信号通路的激活促进NSCLC的进展。我们的研究结果强调,RP11-79H23.3 作为一种抗癌基因,通过隔离 miR-29c 加速 NSCLC 进展,为 NSCLC 提供了一个有希望的治疗靶点。